Abstract. The purpose of this study was to compare the prognosis of graft-percutaneous coronary intervention (PCI) and native vessel (NV)-PCI, drug-eluting stents (DESs) and bare-metal stents (BMSs) for the treatment of graft lesions following coronary artery bypass grafting (CABG), and to determine the risk factors for major adverse cardiac events (MACEs). A total of 289 patients who underwent PCI following CABG between August 2005 and March 2010 were retrospectively analyzed. The effects on survival were compared among patients who underwent NV-and graft-PCI, and DES and BMS implantation. Additionally, the risk factors for MACEs following PCI for graft lesions were analyzed. The findings showed that MACE-free and revascularization-free survival rates were significantly higher in the NV-PCI group compared with those in the graft-PCI group. There were 63 cases (29.0%) of MACEs in the DES group and 25 cases (52.1%) in the BMS group. In patients undergoing NV-PCI, the DES group had significantly fewer MACEs and less target vessel revascularization (TVR) than the BMS group. In patients undergoing graft-PCI, the DES group showed a tendency for fewer MACEs and a lower incidence of cardiac mortality, myocardial infarction and TVR compared with the BMS group. Diabetes, an age of >70 years and graft-PCI were independent risk factors for MACEs in patients post-PCI. It is concluded that NV-PCI has superior long-term outcomes compared with graft-PCI, and should therefore be considered as the first-line treatment for graft disease following CABG. Despite this, graft-PCI remains a viable option. DESs are the first choice for graft-PCI due to their safety and efficacy and their association with reduced mortality and MACE rate. Diabetes, older age and graft-PCI are independent risk factors for MACEs in patients post-CABG who are undergoing revascularization.
Introduction
The annual percentage of recurrences following coronary artery bypass graft (CABG) surgery that require further revascularization therapy, is ~8.6-10.4% (1) . Patients with CABG have a tendency to survive longer, leading to the issue of decreased long term patency rates. The native coronary artery may also develop de novo atherosclerosis, resulting in myocardial ischemia and angina. The 10-year patency rate of the internal mammary artery graft is 85-95%, whereas the 10-year patency rate of saphenous vein grafts (SVG) is only ~40% (2) (3) (4) (5) . Furthermore, 40% of patients with not yet occluded SVG experience various extents of stenosis, the treatment of which has become a common clinical problem (6) (7) (8) . Graft stenosis can be treated with secondary CABG or percutaneous coronary intervention (PCI) in either the native vessel (NV) or the graft. With significantly increased mortality, incidence of myocardial infarction, and perioperative complications, the benefit of secondary CABG is much lower, as compared with first-time CABG. Therefore, PCI has become the preferential option for revascularization following CABG treatment (9) (10) . The optimal percutaneous revascularization strategy for patients with SVG disease subsequent to CABG remains unclear and the results obtained by previous retrospective studies are controversial (11) (12) (13) (14) (15) (16) (17) ; thus, two questions remain unanswered. The first is the choice of target vessel for either the graft or the native coronary artery. The second is whether to use a drug eluting stent (DES) or bare metal stent (BMS) for the PCI. The present study analyzed the clinical and pathological manifestations of patients receiving post-CABG PCI treatment. Furthermore, the risk factors for major adverse cardiac events (MACEs) in patients subjected to PCI post-CABG were investigated and the treatment strategy and prognosis were discussed.
Materials and methods
Study design. Patients undergoing PCI for graft lesions post-CABG, as demonstrated by ischemic symptoms or on angiography, were investigated in the present study. Clinical follow-up and study end-points. Patients undergoing stent implantation at the Tianjin Chest Hospital are routinely followed-up at 6 months, 1 year and annually thereafter by telephone interviews with the patient or family and a review of the medical records. The primary study end-point was all-cause mortality. The secondary study end-point was a composite end-point of one of the following MACEs: Cardiac mortality, non-fatal MI or target vessel revascularization (TVR). MI was defined as the onset of chest pain in combination with new, typical changes in the electrocardiogram and biochemical evidence of myocardial necrosis. Since MIs recorded during the follow-up period could have occurred in any region of the myocardium it was not possible to establish whether the MI was specific to the stented SVG segment. Target lesion revascularization (TLR) was defined as the requirement for a repeated revascularization procedure (either PCI or coronary bypass surgery) due to re-stenosis in the stented segment. TVR was defined as a new revascularization procedure in the target vessel, and also included TLR. Any clinical events arising throughout the study were adjudicated by an independent clinical events committee that was blinded to the treatment assigned to the patient.
Statistical analysis. Continuous variables are expressed as the mean ± standard deviation and were compared with the Student's t-test. Categorical variables are expressed as frequencies and were compared using the χ 2 or Fisher's exact test. The effects on survival were compared between the NV-PCI and graft-PCI, and DES and BMS groups using the Kaplan-Meier survival curve and log-rank test. Risk factors for MACEs post-PCI were analyzed with multivariable Cox regression models. Odds ratios (ORs) and the 95% confidence intervals (95% CIs) were used to express relative risk. SPSS software (version 18.0; SPSS Inc., Chicago, IL, USA) was used for the statistical analysis. All the tests were two-tailed, and P<0.05 was considered to indicate a statistically significant difference.
Results

Baseline clinical characteristics.
Baseline patient demographic data are listed in Table I .
Long-term follow-up outcomes. Among the 289 cases, only 24 were lost to follow-up (8.3%), leaving a total of 265 patients who were followed. The mean follow-up time was 37 months (range, 6-78 months). Eighty-eight cases of MACEs occurred (Table IV) .
Discussion
The 10-year patency rate of the internal mammary artery graft has been previously reported to be 85-95% (5) compared with only 40% for SVGs (6) . Approximately 40% of unoccluded SVGs may develop stenosis (6) . Patients with diseased graft vessels are older and the primary coronary lesion prior to CABG is often severe (10) . Grafts, and particularly SVGs, usually deteriorate within 3 years, resulting in ischemia and refractory heart failure with a poor prognosis (19) . Graft lesions following CABG have remained an important clinical challenge. Graft revascularization can be achieved with a second CABG or PCI; however, a second CABG can be difficult, with an increased incidence of complications and mortality, and inferior results with regard to symptom relief, graft patency and event-free survival (20) . Older age, systematic atherosclerosis, vital organ dysfunction and malignancy are also contraindications for a second CABG. In addition, potential donor sites for a new graft are sparse following two or more attempts at CABG. PCI has therefore become the preferred mode of treatment for graft lesions, the majority of which are SVGs (10) . PCI has also become the first-line treatment for post-CABG myocardial ischemia due to its excellent safety and efficacy (21) (22) .
NV-PCI and graft-PCI are the two options for graft revascularization following CABG. Graft-PCI shows superior outcomes to repeated CABG; however, graft-PCI is complex due to the anatomy of the saphenous vein and results in low success rates (23) . Graft-PCI is easily complicated by distal thrombosis during the procedure, post-procedural re-stenosis and unconfirmed long-term efficacy; therefore, current guidelines do not recommend PCI for the treatment of completely occluded grafts (22, 24, 25) . PCI for graft stenosis is optional when the NV is totally occluded, has diffuse lesions, failed opening or is unlikely to open, as judged by the surgeon. With sufficient training and a good surgical technique, NV-PCI does not require highly specialized instrumentation and, with sufficient training, it is a straightforward surgical procedure. Compared with graft-PCI, NV-PCI has a higher success rate in complicated coronary disease (26) . The reopened native coronary artery is preferred due to its long-term durability compared with the degenerated SVG; however, the complexity of NV lesions affects the success rate of PCI (11-13).
Comparison studies of different PCI strategies for post-CABG graft lesions show conflicting findings (27-29). Presented as the mean ± standard deviation. DES, n=239; BMS, n=50. DES, drug-eluting stent; BMS, bare-metal stent; PCI, percutaneous coronary intervention; NV, native vessel; MI, myocardial infarction; CHD, coronary heart disease; SA, stable angina; UA, unstable angina; STEMI, ST segment elevation myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; BMI, body mass index; FBG, fasting blood glucose; FIB, fibrinogen; CHO, cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; GpIIb/IIIa, glycoprotein IIb/III. 
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In a study with 1,000 patients with a mean follow-up time of 29 months, SVG-PCI was shown to have a 2.1-fold mortality risk and 1.6-fold MACE occurrence compared with NV-PCI (27) . In a prospective study including 190 patients with post-CABG NV-PCI and 88 patients with graft-PCI, the graft-PCI group had significantly higher incidence rates of MACEs, mortality and TVR than the NV-PCI (29) . In the present study, 265 patients completed the follow-up, with a significantly higher proportion of NV-PCI cases than graft-PCI cases (190 NV-PCI and 75 graft-PCI). Seventy-five patients with graft-PCI had completely occluded NVs, failed opening due to diffuse lesions or unlikely opening, as determined by the surgeon. The mean follow-up time was 37 months, during which the incidence of MACEs was 33.2% (mortality, 6.4%; MI, 6.8%; TVR, 20.2%). The NV-PCI group had an improved prognosis and higher MACE-free and revascularization-free survival compared with the graft-PCI group. We thus recommend that NV-PCI be used as the first-line treatment for post-CABG graft disease. In the case of failed NV-PCI, graft-PCI can be considered.
The two major types of stents available for PCI following CABG are BMSs and DESs. Re-stenosis can significantly affect the efficacy of SVG-PCI (30) . A meta-analysis revealed DESs to be superior to BMSs in SVG-PCI (31). Hakeem et al (31) analyzed 29 studies with a total of 7,994 patients (4,187 with DESs and 3,807 with BMSs) and a mean follow-up time of 6-48 months. In their meta-analysis, DESs were found to be superior to BMSs with regard to the incidence rates of MACEs (19 vs. 28%, P<0.00001), mortality (31) . By contrast, other studies did not find DESs to be superior to BMSs in the long-term follow-up subsequent to SVG-PCI (17, 32, 33) . The SOS study (17) found that the overall mortality rate did not differ significantly between the DES and BMS groups at the end of 1.5 years of follow-up (5 vs. 12%; HR, 1.56; 95% CI, 0.72-4.11; P=0.27). In a study of 284 patients with DESs and 95 patients with BMSs, the incidence of MACEs at 3 years did not differ significantly between the groups, despite a significantly higher inpatient mortality rate in the BMS group. This suggested a good safety profile (but non-superiority) of DESs in long-term implantation (33) .
In the present study, DESs were employed in 239 patients (82.7%) and BMSs in 50 patients (17.3%), who were followed up for a mean period of 37 months. There was a trend towards an improved outcome in the DES group compared with the BMS group. In patients undergoing NV-PCI, DESs were superior to BMSs with regard to the incidence rates of MACEs and TVR, but no significant differences in mortality and MI were found between the groups. In patients undergoing graft-PCI, DESs were implanted in 56 patients and BMSs in 19 patients. The DES group showed a tendency for lower incidence rates of MACEs, cardiac mortality, MI and TVR.
It should be acknowledged that there were several limitations to the present study. Firstly, the design of the study was retrospective and non-randomized, and the course of treatment was determined by the individual surgeon. Secondly, antiplatelet treatment was administered for a variable duration and there was a lack of routine angiographic follow-up. Additionally, the length of the time-frame for inclusion in this study (5 years) may have introduced confounding effects as a result of developments in techniques and equipment. Finally, the use of BMSs in the graft-PCI procedures was relatively low. A prospective, randomized study with angiographic follow-up is therefore warranted to control for confounding factors. Despite these limitations, however, the present study has collated the information for a large patient population and reports the clinical presentation and outcomes of SVG disease treatment in routine, daily practice.
In conclusion, NV-PCI has an improved long-term prognosis compared with graft-PCI in the treatment of post-CABG graft disease. NV-PCI should be considered as the first-line treatment for graft lesions, but graft-PCI remains a viable option. There is insufficient data on the long-term efficacy and safety of DESs and BMSs in SVG-PCI; however, compared with BMSs, DESs are currently the preferred stents for SVG-PCI.
